Phys.OrgPhoto-responsive protein hydrogels as agent for controlled stem cell/protein releasePhys.OrgHydrogels, noted for their biomimetic properties, are the leading materials for biomedical applications, such as drug delivery and stem cell therapy. Tr… Continue reading
Phys.OrgPhoto-responsive protein hydrogels as agent for controlled stem cell/protein releasePhys.OrgHydrogels, noted for their biomimetic properties, are the leading materials for biomedical applications, such as drug delivery and stem cell therapy. Tr… Continue reading
EurekAlert (press release)A new molecular scissors act like a GPS to improve genome editing …EurekAlert (press release)Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1,… Continue reading
|
BeiGene, Celgene Ink Up-to-$1.393B Cancer Immunotherapy Deal
Genetic Engineering & Biotechnology News Celgene will take a 5.9% stake in BeiGene in an up-to-$1.393 billion cancer immunotherapy deal that will catapult the U.S.-based biotech giant to a top position in programmed death protein-1 (PD-1) checkpoint inhibitors, the companies said today … |
|
Shire Submits Application To US FDA For Gene Therapy For Hemophilia
Interactive Investor The company said the application, which was based on the results of pre-clinical and phase one studies, to the FDA represented the “latest step forward for Shire’s gene therapy program, which shows promise for both hemophilia A and B populations”. Shire submits investigational New Drug Application to FDA for Gene …Nasdaq BRIEF-Shire submits IND application for gene therapy candidate SHP654Reuters |